Andreas Liebl

Summary

Country: Germany

Publications

  1. ncbi Evaluation of risk factors for development of complications in Type II diabetes in Europe
    A Liebl
    Diabetes Center, Fachklinik Bad Heilbrunn, Wörnerweg 30, 83670 Bad Heilbrunn, Germany
    Diabetologia 45:S23-8. 2002
  2. ncbi A reduction in severe hypoglycaemia in type 1 diabetes in a randomized crossover study of continuous intraperitoneal compared with subcutaneous insulin infusion
    A Liebl
    Center for Diabetes and Metabolism, Fachklinik, Woernerweg 30, Bad Heilbrunn, Germany
    Diabetes Obes Metab 11:1001-8. 2009
  3. ncbi The when and how of insulin initiation in type 2 diabetes
    Andreas Liebl
    Center for Diabetes and Metabolism, Fachklinik Bad Heilbrunn, Germany
    Curr Med Res Opin 23:129-32. 2007
  4. ncbi [Postprandial blood glucose as the driving force in pathogenesis of type 2 diabetes]
    Andreas Liebl
    Diabetes und Stoffwechselzentrum und Abteilung für Innere Medizin, Fachklinik Bad Heilbrunn
    Med Klin (Munich) 98:7-11. 2003
  5. ncbi [Costs of long-term complications in type 2 diabetes patients in Germany. Results of the CODE-2 Study]
    Andreas Liebl
    Fachklinik Diabetes und Stoffwechselzentrum, Bad Heilbrunn
    Med Klin (Munich) 97:713-9. 2002
  6. ncbi Challenges in optimal metabolic control of diabetes
    Andreas Liebl
    Center for Diabetes and Metabolism Wallberg Clinic, Rottach Egern, Germany
    Diabetes Metab Res Rev 18:S36-41. 2002
  7. ncbi Clinical Outcomes After Insulin Initiation in Patients with Type 2 Diabetes: 24-Month Results from INSTIGATE
    Andreas Liebl
    Centre for Diabetes and Metabolism, Fachklinik Bad Heilbrunn, Bad Heilbrunn, Germany
    Diabetes Ther 3:9. 2012
  8. ncbi Clinical outcomes after insulin initiation in patients with type 2 diabetes: 6-month data from the INSTIGATE observational study in five European countries
    Andreas Liebl
    Centre for Diabetes and Metabolism, Fachklinik Bad Heilbrunn, Bad Heilbrunn, Germany
    Curr Med Res Opin 27:887-95. 2011
  9. ncbi Comparison of insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER Study: a randomized controlled trial
    A Liebl
    Center for Diabetes and Metabolism, Fachklinik Bad Heilbrunn, Germany
    Diabetes Obes Metab 11:45-52. 2009
  10. ncbi Ten years of experience with biphasic insulin aspart 30: from drug development to the latest clinical findings
    Andreas Liebl
    Fachklinik Bad Heilbrunn, Bad Heilbrunn, Germany
    Drugs 72:1495-520. 2012

Detail Information

Publications17

  1. ncbi Evaluation of risk factors for development of complications in Type II diabetes in Europe
    A Liebl
    Diabetes Center, Fachklinik Bad Heilbrunn, Wörnerweg 30, 83670 Bad Heilbrunn, Germany
    Diabetologia 45:S23-8. 2002
    ..The Cost of Diabetes in Europe - Type II study is the first large coordinated attempt to measure the current standard of care and determine the costs of managing patients with Type II (non-insulin-dependent) diabetes mellitus...
  2. ncbi A reduction in severe hypoglycaemia in type 1 diabetes in a randomized crossover study of continuous intraperitoneal compared with subcutaneous insulin infusion
    A Liebl
    Center for Diabetes and Metabolism, Fachklinik, Woernerweg 30, Bad Heilbrunn, Germany
    Diabetes Obes Metab 11:1001-8. 2009
    ....
  3. ncbi The when and how of insulin initiation in type 2 diabetes
    Andreas Liebl
    Center for Diabetes and Metabolism, Fachklinik Bad Heilbrunn, Germany
    Curr Med Res Opin 23:129-32. 2007
    ..Recent findings were identified via a literature search using PubMed during the last 5 years in addition to key congress abstract searches from the last 2 years...
  4. ncbi [Postprandial blood glucose as the driving force in pathogenesis of type 2 diabetes]
    Andreas Liebl
    Diabetes und Stoffwechselzentrum und Abteilung für Innere Medizin, Fachklinik Bad Heilbrunn
    Med Klin (Munich) 98:7-11. 2003
    ..So acarbose has the potential to reduce postprandial hyperglycemia, which is the driving force for diabetes, and thus can prevent diabetes mellitus type 2...
  5. ncbi [Costs of long-term complications in type 2 diabetes patients in Germany. Results of the CODE-2 Study]
    Andreas Liebl
    Fachklinik Diabetes und Stoffwechselzentrum, Bad Heilbrunn
    Med Klin (Munich) 97:713-9. 2002
    ..Costs of three major complications (ulcer, amputation, and stroke/PRIND) were determined. Here, comorbidities with other major complications were excluded...
  6. ncbi Challenges in optimal metabolic control of diabetes
    Andreas Liebl
    Center for Diabetes and Metabolism Wallberg Clinic, Rottach Egern, Germany
    Diabetes Metab Res Rev 18:S36-41. 2002
    ....
  7. ncbi Clinical Outcomes After Insulin Initiation in Patients with Type 2 Diabetes: 24-Month Results from INSTIGATE
    Andreas Liebl
    Centre for Diabetes and Metabolism, Fachklinik Bad Heilbrunn, Bad Heilbrunn, Germany
    Diabetes Ther 3:9. 2012
    ..To examine changes in insulin regimens and glycemic control during the 24 months after initiation of insulin in patients with type 2 diabetes mellitus...
  8. ncbi Clinical outcomes after insulin initiation in patients with type 2 diabetes: 6-month data from the INSTIGATE observational study in five European countries
    Andreas Liebl
    Centre for Diabetes and Metabolism, Fachklinik Bad Heilbrunn, Bad Heilbrunn, Germany
    Curr Med Res Opin 27:887-95. 2011
    ..To examine insulin regimens and factors that affect glycaemic control at 6 months after initiation of insulin therapy in patients with type 2 diabetes mellitus...
  9. ncbi Comparison of insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER Study: a randomized controlled trial
    A Liebl
    Center for Diabetes and Metabolism, Fachklinik Bad Heilbrunn, Germany
    Diabetes Obes Metab 11:45-52. 2009
    ..Insulin analogues are widely used but few data exist comparing different analogue regimens. We compared two such regimens in type 2 diabetes mellitus (T2DM) uncontrolled by oral antidiabetic agents (OADs) with or without basal insulin...
  10. ncbi Ten years of experience with biphasic insulin aspart 30: from drug development to the latest clinical findings
    Andreas Liebl
    Fachklinik Bad Heilbrunn, Bad Heilbrunn, Germany
    Drugs 72:1495-520. 2012
    ..In conclusion, BIAsp 30 offers a simple and flexible option for insulin initiation and intensification that provides coverage of both fasting and prandial glucose...
  11. ncbi Treat early, treat appropriately
    Andreas Liebl
    Center for Diabetes and Metabolism, Fachklinik, Bad Heilbrunn, Germany
    Prim Care Diabetes 4:S3-10. 2010
    ..This review examines how patients with type 2 diabetes are currently managed across several European countries, and explores the evidence around insulin use in type 2 diabetes and the implications for primary care...
  12. ncbi Direct costs and health-related resource utilisation in the 6 months after insulin initiation in German patients with type 2 diabetes mellitus in 2006: INSTIGATE study
    A Liebl
    Fachklinik Bad Heilbrunn, Bad Heilbrunn, Germany
    Curr Med Res Opin 24:2349-58. 2008
    ..To assess direct costs and describe resource utilisation associated with the first 6 months of insulin therapy in German patients with type 2 diabetes mellitus (DM)...
  13. ncbi Bootstrap confidence intervals for costs-of-illness of type 2 diabetes mellitus in Germany
    Stefan Wagenpfeil
    Institute for Medical Statistics and Epidemiology, Technical University Munich, Ismaninger Strasse 22, 81675 Munich, Germany
    Value Health 5:398-404. 2002
    ..The Costs of Diabetes in Europe-Type 2 study (CODE-2, SmithKline Beecham plc) measures costs of managing patients with type 2 diabetes mellitus in Germany. The aim of this analysis was to assess the uncertainty of these estimates...
  14. ncbi Efficacy of biphasic insulin aspart in patients with type 2 diabetes
    Serge Halimi
    Department d Urologie, Nephrologie et Endocrinologie, Centre Hospitalier Universitaire de Grenoble, Grenoble, France
    Clin Ther 27:S57-74. 2005
    ..It would be expected that these pharmacokinetic improvements would enhance clinical performance. However, the efficacy of BIAsp 30 compared with other common treatment regimens has not yet been systematically reviewed...
  15. ncbi Premixed insulin treatment for type 2 diabetes: analogue or human?
    Alan J Garber
    Baylor College of Medicine, Faculty Center, Houston, TX 77030, USA
    Diabetes Obes Metab 9:630-9. 2007
    ..Overall, the evidence suggests that premixed insulin analogues are cost effective and have useful advantages over premixed human insulin for the treatment of type 2 diabetes...
  16. ncbi Cost-effectiveness of rosiglitazone oral combination for the treatment of type 2 diabetes in Germany
    Arran T Shearer
    York Health Economics Consortium, University of York, Heslington, UK
    Pharmacoeconomics 24:35-48. 2006
    ..To assess the cost-effectiveness of rosiglitazone in combination with other oral agents for the treatment of overweight and obese patients with type 2 diabetes in Germany...
  17. ncbi Postprandial glucose and its role in type 2 diabetes
    Jaime Davidson
    Hormones (Athens) 5:1 p following 217. 2006